Document Type

Article

Publication Date

2-27-2025

Identifier

DOI: 10.15585/mmwr.mm7406a2

Abstract

Annual influenza vaccination is recommended for all persons aged ≥6 months in the United States. Interim influenza vaccine effectiveness (VE) was calculated among patients with acute respiratory illness-associated outpatient visits and hospitalizations from four VE networks during the 2024-25 influenza season (October 2024-February 2025). Among children and adolescents aged <18 >years, VE against any influenza was 32%, 59%, and 60% in the outpatient setting in three networks, and against influenza-associated hospitalization was 63% and 78% in two networks. Among adults aged ≥18 years, VE in the outpatient setting was 36% and 54% in two networks and was 41% and 55% against hospitalization in two networks. Preliminary estimates indicate that receipt of the 2024-2025 influenza vaccine reduced the likelihood of medically attended influenza and influenza-associated hospitalization. CDC recommends annual receipt of an age-appropriate influenza vaccine by all eligible persons aged ≥6 months as long as influenza viruses continue to circulate locally.

Journal Title

MMWR. Morbidity and mortality weekly report

Volume

74

Issue

6

First Page

83

Last Page

90

MeSH Keywords

Humans; Influenza Vaccines; United States; Influenza, Human; Adolescent; Child; Adult; Child, Preschool; Infant; Young Adult; Middle Aged; Seasons; Aged; Hospitalization; Vaccine Efficacy

PubMed ID

40014791

Keywords

Influenza Vaccines; United States; Human Influenza; Seasons; Hospitalization; Vaccine Efficacy

Comments

The MMWR series of publications is published by the Center for Surveillance, Epidemiology, and Laboratory Services, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Service.

Download

Plum Print visual indicator of research metrics
PlumX Metrics
  • Usage
    • Downloads: 6
    • Abstract Views: 3
see details

Share

COinS